Abstract
Polymeric technological breakthroughs in the field of nanotechnology have drastically fueled the use of drug delivery systems. Poly(lactic-co-glycolic acid) (PLGA) has emerged as a promising, biodegradable, US-FDA approved polymer. PLGA can be fabricated into particles of various sizes and shapes and can be utilized to entrap a diverse range of therapeutics with a broad range of molecular weights. Drug delivery employing PLGA nanoparticles (NPs) has received a lot of attention in the past 2 decades. The size (<200nm) of NPs makes them extremely advantageous for tumor-targeted drug delivery since angiogenic tumors tend to generate permeable vasculature and can passively accumulate circulating NPs (enhanced permeability and retention effect). However, they are also versatile in conjugating with a variety of micro and macro biomolecules that can target the drug-loaded NPs to a specific site of action. Recently it has also been shown that NPs can be cloaked using cell membrane, a process termed nano-ghosting, which imparts the molecular fingerprint of the cell and can enable preferential interaction with tumor tissue. In this chapter we will discuss different targeting strategies to formulate PLGA-based nanoparticles for application in different pathological conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
